Although leptomeningeal carcinomatosis is a well-established clinical syndrome, virtually nothing is known about the tumor cells responsible for this particularly aggressive metastatic process. To isolate cerebrospinal fluid-derived tumor cells ("CSFTCs") from 15 metastatic breast cancer patients diagnosed with leptomeningeal carcinomatosis, CSF samples were subjected to a two-step method involving immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS), a technique previously used for isolating circulating tumor cells (CTCs) from blood.
Introduction
Leptomeningeal carcinomatosis, in which tumor cells metastasize to the leptomeninges and cerebrospinal fluid (CSF), is a particularly virulent syndrome with extremely high morbidity and mortality (1) (2) (3) (4) (5) . Furthermore, central nervous system (CNS) involvement of breast cancer, including leptomeningeal carcinomatosis, appears to be increasing due to longer survival times and more efficacious treatment against other sites of systemic disease (6) . The particularly aggressive nature of leptomeningeal carcinomatosis and its increasing frequency highlight the importance of understanding the biology of CSFTCs. Despite efforts towards improving detection and diagnosis (7) , almost no information exists regarding the underlying biology and molecular characteristics of these metastatic cells.
We have developed new methods for the isolation and molecular analysis of circulating tumor cells (CTCs) from the blood of metastatic cancer patients (8) (9) (10) . This approach involves the efficient and complete isolation of CTCs without significant leukocyte or non-malignant epithelial cell contamination, followed by array comparative genomic hybridization (aCGH). It was therefore of interest to adapt this approach for isolation and profiling of CSFTCs, including gene expression and mutation analyses as well as aCGH. In a subset of patients, we compared were also sorted and defined as: nucleated, EPCAM-negative, and CD45-positive. The cell inputs for genomic and gene expression profiling are listed in Table S1 .
Genomic profiling
Genome-wide copy number analysis of IE/FACS-isolated cells was performed as previously described (8) (9) (10) . Briefly, genomic DNA was subjected to whole genome amplification using the GenomePlex® Single Cell Whole Genome Amplification Kit (WGA4) and closely adhering to manufacturer's instructions. The resulting amplified DNA was then analyzed for copy number aberrations by bacterial artificial chromosome (BAC) array comparative genomic hybridization (CGH) analysis.
Somatic mutation analysis
WGA4-amplified DNA samples were screened for mutations using the Sequenom™ MassARRAY System (Sequenom, San Diego, CA). The MassARRAY platform involves the PCR amplification of the region containing the mutation, followed by a single base extension using mass-tagged primers and mass spectrometry (MALDI-TOF MS) of extended primers. The analysis was performed as a contract service at the Pathology Translational Research Laboratory, Oregon Health & Science University following manufacturer's instructions and also as previously described (12) . The Sequenom OncoCarta Panel version 2.0 assays, designed to detect 152 somatic mutations across 18 oncogenes and tumor suppressors, were used for the analysis. Candidate mutations were identified using an automated calling algorithm (Sequenom Typer software). Mass spectra were visually inspected to confirm putative mutations. A proof-ofconcept experiment performed on non-amplified and WGA4-amplified DNA from cell culture Author Manuscript Published OnlineFirst on October 18, 2013; DOI: 10.1158/0008-5472.CAN- consistently detected the known mutation PIK3CA E545K in this cell line as listed in the Catalogue of Somatic Mutations in Cancer (COSMIC) database (Table S2) .
Gene expression analysis
QPCR analysis was performed on 64 cancer-related genes chosen from a previously reported expression profiling of CTCs (13) ( Table S3 ). In addition to CSFTCs, leukocytes defined as: nucleated, EpCAM-negative, and CD45-positive were also sorted by FACS from the same enriched CSF sample and served as non-tumor controls. EPCAM and PTPRC (encodes CD45), two genes included in the list, are markers specific for epithelial cells and hematopoietic cells, respectively. Also included are 6 candidate reference genes for normalization of gene expression data (see Statistical Analysis section). A custom Taqman® Low Density Array (TLDA, Applied Biosystems) microfluidic card (384-well format) was designed to contain two sets of the 64 Taqman® gene expression assays printed in triplicate. Cell lysis, reverse transcription (RT), and preamplification were performed using Taqman® PreAmp Cells-to-CT™ kit (Ambion, Texas) following manufacturer's instructions. Amplified cDNA was subjected to QPCR analysis using the ABI PRISM 7900HT to obtain cycle threshold (Ct) values.
Quality control
Quality control (QC) of DNA and RNA from CSFTC samples and resulting data (see Table S1 ) was performed as previously described (9, 13) . For DNA profiling, amplified DNA was subjected to a multiplex PCR analysis to detect the presence of the housekeeping gene, GAPDH. Samples containing the amplifiable sequences (100, 200, 300 and 400bp) of GAPDH were considered for CGH analysis. The median absolute deviation (MAD) estimates were used as a measure of quality of the array data. Array data with MAD estimate ≥0.25 were considered noisy and were excluded from the analysis (9) . For RNA profiling, pre-amplified cDNA was analysis, suggesting low quantity and low quality of RNA. Therefore, samples meeting these criteria were excluded from further analysis. After TLDA RT-PCR analysis, samples with less than 20% detection, i.e., detection of ≤12 of the 64 genes, were excluded from the analysis. In addition, since GAPDH and ACTB were chosen as reference genes to calculate for ∆Cts, samples with no detection (missing values) for either of these genes were also excluded from the analysis.
Statistical Analysis
Array CGH microarray data was analyzed using Nexus 6.1 software (Biodiscovery) as previously described (8) . The thresholds of log2 ratio values for single copy number gains and losses were 0.20 and −0.20, respectively; the thresholds for high-level number gains and homozygous deletions were 0.6 and −0.6, respectively. The rank segmentation algorithm was used to estimate copy number using the significance threshold of p-value <0.001. Regions of gains and losses present in ≥ 50% of each sample were considered recurrent. Results of the copy number analysis was compared to previously published aCGH data from primary breast tumors (14) and CTCs (9) that were processed in a manner similar to that of the samples in this dataset.
All three datasets were obtained from hybridization using similar BAC arrays printed by the UCSF Array Core. We performed a Fisher's Exact test in Nexus 6.1 to determine regions that were differentially gained or lost between cohorts. For higher stringency, we increased the cutoff to 35% as compared to 30% in our previous study (9) . Therefore, gains and losses with an absolute difference of ≥35% between datasets with a p-value less than 0.05 were considered statistically significant. Of note, the sequential position of the clones was considered during segmentation to minimize possible batch effects between datasets.
Genomic plots were generated as previously described (9) . Briefly, microarray data was subjected to circular binary segmentation (CBS) (15) , as implemented in the DNAcopy package from Bioconductor (16) , to translate intensity measurements into regions of equal copy numbers and to make gain, loss, and amplification calls. Enrichment tests were done at the arm level to identify significantly gained and lost chromosome arms (9) . The extent of the genomic instability, defined as the fraction of genome altered (FGA), was calculated as previously described (17) . Briefly, the FGA for each sample was calculated by assigning each clone a distance equal to the sum of one half of the distance between its own center and that of its neighboring clones.
Concordance between two aCGH profiles was calculated using the weighted Pearson correlation coefficient (r w ) as previously described (9) . Correlation coefficients falling in the corresponding intervals, 0 to <0.36, 0.36 to <0.68, 0.68 to <0.90, 0.90 to 1.0 were said to have weak, moderate, high, and very high correlation, respectively (18) . The overall concordance of gains and losses between copy number datasets [this study vs CTCs (9) vs primary breast tumors (14) ] was measured by estimating the concordance correlation coefficient (r c ) of the proportion of gains and losses, as described previously (9 ). For example, a log 10 RQ = 0 indicates no differential expression between test (CSFTC) versus calibrator (CD45) samples while a log 10 RQ = 1 and -1 indicates a ten-fold increase or decrease, respectively, in test versus calibrator samples. MIAME compliant copy number and gene expression data have been deposited into GEO under accession # GSE46068.
Results

Patient characteristics
This study included 15 metastatic breast cancer patients diagnosed with leptomeningeal carcinomatosis by standard cytological detection of malignant cells in the CSF (14 patients) or atypical cells in the CSF with positive MRI showing leptomeningeal disease (1 patient). The median age was 51 years ( Table 1) . Eleven (73%) patients were ER positive, seven (47%) were HER2 positive, and two (13%) were triple negative. Ten (67%) patients were also diagnosed with brain metastasis.
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Isolation and genomic profiling of CSFTCs
We evaluated the feasibility of applying our approach for CTC profiling (IE/FACS isolation followed by WGA/CGH) to genome-wide copy number analysis of CSFTCs. Nineteen CSF samples from 15 patients were obtained via lumbar puncture (n=11) or via an Ommaya reservoir (n=8). The samples were then subjected to IE/FACS for CSFTC isolation; genomic DNA was then amplified by WGA and analyzed by aCGH (Fig. S1) . Seventeen of the 19 samples (89%) from 13 patients passed quality control (Fig. S2 , Table S1 ).
The resulting CSFTC profiles demonstrated a wide range of genomic aberrations, confirming that the isolated cells were indeed cancer cells (Fig. 1) . This is important since it was not clear whether nonmalignant EPCAM-expressing cells, which would be isolated by IE/FACS, might be present at low levels within CSF. Common aberrations (present in ≥50% of the samples) included gains on 1q, 8q and 20q, as well as losses on 1p, 3p, 3q, 4p, 8p, and 11p (Table 2) . Notably, 12 out of 13 CSFTC samples (92%) harbored gains on 8q24, including the MYC oncogene ( Table 2) .
We compared the CSFTC profiles with those from a series of primary breast tumors, as reported previously (14) . CSFTCs and primary tumors showed many concordant copy number alterations across the genome (r c gain=0.75 and r c loss=0.59) (Fig. S3A) . We next compared CSFTC profiles with those obtained from a series of breast CTCs, as reported previously by us (9) . CSFTCs and CTCs also showed many concordant copy number alterations across the genome (r c gain=0.72 and r c loss=0.60) (Fig. S3A) . We then performed differential copy number analysis to explore potential regions of divergence among CSFTCs, primary tumors and CTCs.
Results of this exploratory analysis revealed several alterations that were observed more frequently in CSFTCs than in primary tumors, such as gains in 8q24 (including MYC) ( 
Enumeration, isolation and genomic profiling of CTCs
Blood samples were collected from 6 of the 15 patients. CTCs were enumerated in 7.5mL of blood using the CellSearch protocol. Three patients had ≥5 CTCs in 7.5mL blood, while 2 patients had undetectable CTCs in blood despite having CSFTCs ( Table 1 
Genomic profiles of CSFTCs vs. matched primary tumors
In a subset of patient samples (n = 6) for which CSFTC isolation and profiling were performed, samples from the corresponding primary tumors were also obtained and successfully analyzed by CGH.
Overall, CSFTC samples showed many conserved alterations when compared to their respective primary tumor (r c gain=0.76 and r c loss=0.43) (Fig. S4A ). However, high-level gains centered on 8q24 (including the MYC locus) were frequently seen in CSFTCs but were not observed in archival tumors (Fig. S4B) . Furthermore, genomic changes in the CSFTC set were generally more extensive (i.e., new alterations or higher levels of gains/losses in the same loci) than in the primary tumor set. To assess this quantitatively, we compared the fraction of genome altered (FGA) of CSFTCs versus matched primary tumors. CSFTCs showed a significantly higher FGA at 23% as compared to primary tumors at 14% (p=0.0277, sign test), suggesting that CSFTCs were more genomically aberrant than their corresponding primary tumor samples.
Alternatively, it is possible that CSFTC samples contained a higher proportion of true tumor cells, due to the IE/FACS isolation procedure, than the primary tumor samples; greater purity would reduce any signal dilution from normal DNA associated with stromal or other non-tumor cell components.
Details of the 6 CSFTC cases as compared to their corresponding primary tumors, and in some cases to additional local regional or metastatic tumor tissue, are discussed below. A complete list of gained and lost arms for each sample can be found in Table S6 . Seven additional cases are discussed in Supplementary Information (also see (Fig. 2A) . Fine needle aspirate of the intact primary tumor collected a day prior to CSF collection was also profiled, and overall revealed similar genomic alterations (FGA=0.14). Comparison of CSFTCs to the primary tumor revealed moderate concordance (r w =0.54), including shared gains in 8q and 9p. The primary tumor contained a single copy loss in 3p, which appeared as a homozygous deletion in CSFTCs, and a gain in 5q, which appeared to be deleted in CSFTCs.
Patient 4039 is a 51-year-old woman with ER positive, PR positive, and HER2 negative MBC. Seven CSFTCs were isolated and profiled by aCGH (Fig. 2B) . The corresponding archival primary tumor from 7.4 years prior to CSF collection was also obtained and profiled. (Fig. 2D) . Primary tumor specimen from a core biopsy performed approximately 3 months prior to CSF collection was retrieved and profiled by aCGH. The primary tumor contained somewhat fewer genomic alterations (FGA=0.18), but generally showed moderate concordance with CSFTCs (r w =0.50). Shared alterations included gains in 1q, 8q, 10p, 11p, and HER2 amplification on 17q21 and losses on 8p and 12p. However, the focal amplification on 1p32-34 seen in CSFTCs was not observed in the primary tumor.
Patient 4015 is a 54-year-old woman with ER negative, PR negative, and HER2 negative (Fig. 3A) . FISH analysis confirmed gene amplification of the MYC locus as well as multiple copies of the centromeric region of chromosome 8 ( Fig. 3B; Supplementary Methods (19) (Fig. S6B) . The aCGH profile of the corresponding primary tumor specimen from 9 months prior to initial CSF sampling showed multiple genomic alterations (FGA=0.24), including shared copy number changes and overall high concordance with CSFTCs (mean r w =0.87, s.d. 0.04).
HER2 status
The HER2 status of CSFTCs was assessed via aCGH analysis and compared with clinical primary tumor HER2 results determined by IHC/FISH. All 13 patients showed concordance between CSFTC HER2 and the clinical HER2 status ( Table 1) . Patient 4011, from whom 5 serial CSFTC profiles were obtained, yielded a complex set of results. Her initial CSFTC sample showed no HER2 copy number gains by aCGH, and her primary tumor was similarly HER2 negative by clinical IHC. However, her four subsequent CSFTC samples showed HER2 copy gains by aCGH, as did her primary tumor. These results suggest that the patient had low level HER2 copy gain in both primary tumor and CSFTCs, detectable by aCGH.
For the 6 cases with paired CSFTC and primary tumor profiles, 5 (83%) exhibited concordant HER2 copy number status using the same aCGH technique. The only case not clearly concordant was patient 4011, who displayed mixed HER2 results as discussed above.
Somatic mutation profiling
In addition to aCGH analysis, we explored the feasibility of mutation screening in CSFTCs. After CSFTC isolation by IE/FACS and WGA, 3 of the CSFTC cases with corresponding primary tumor (patients 4015, 4038, and 4037) were assayed for 152 candidate mutations using the Sequenom™ MassARRAY System ( Table S2) detected in matched CD45+ leukocytes obtained from the same CSF sample. In patient 4038, the PI3KCA H1047R mutation was detected in both CSFTCs and the matched primary tumor. In patient 4037, no mutations were observed in either the CSFTCs or the primary tumor.
Gene expression profiling
To complement these DNA based analyses, we also performed an exploratory gene expression analysis of CSFTCs (Fig. S1) . We isolated CSFTCs in 24 samples from 6 patients obtained via lumbar puncture (n=5) or Ommaya reservoir (n=19). Gene expression profiles of CSFTCs were not compared with those of primary tumors in this study. Only archival tissue was obtainable in select patients, which was amenable to aCGH analysis but not expression profiling.
After QC testing, 18 CSFTC samples (75%) from 5 patients were successfully analyzed for the expression of 64 genes (Fig.S2, Table S1 , Table S3 ). As a negative control, matching leukocyte (CD45+) samples were isolated from the same CSF samples and were successfully profiled.
Unsupervised hierarchical clustering analysis revealed 3 distinct clusters: 2 clusters containing only CSFTCs and one cluster containing the CD45+ samples (Fig. 4A) . In general, serial samples isolated from the same patient clustered together. Differential expression analysis of CSFTCs vs. matching leukocytes showed, as expected, that CSFTCs have high mRNA levels of EPCAM (Log 10 RQ = 3.14, adj p = 0.01) and low levels of PTPRC/CD45 (Log 10 RQ = -4.08, adj p = 0.005) (Fig. 4B) . These results confirm the validity of our CSFTC isolation strategy, which requires surface EPCAM protein in conjunction with absence of detectable CD45 protein (Fig.   4B) . We also observed significant up-regulation of other genes in CSFTCs, such as AGR2 (Log 10 RQ =3.53, adj p = 0.0007), TFF3 (Log 10 RQ = 3.21, adj p = 0.0007), and GRB7 (Log 10 RQ = 2.86, adj p = 0.01) ( Table S3) . Overexpression of these genes has been correlated with aggressive cancer biology (20) (21) (22) (23) (Log 10 RQ=0.85) was up-regulated in CSFTCs as compared to leukocytes (Table S3) .
Additionally, ERBB2 (HER2) expression was almost 3 orders of magnitude higher in CSFTCs than in leukocytes, which is consistent with the known minimal expression of HER2 mRNA in hematopoietic cells (24, 25) (Table S3, Fig. 4C ).
Discussion
The Our report is, to our knowledge, the first to provide detailed profiling of tumor cells isolated from the CSF, including genome-wide copy number, gene expression and mutation analyses. Although we previously described our approach for isolation and aCGH profiling of CTCs (8) (9) (10) , the significance of the present work is the demonstration that similar methods can be used to study CSF tumor cells, which are directly responsible for the notably aggressive clinical syndrome of leptomeningeal carcinomatosis. Unlike CTC detection, which is neither 
necessary nor sufficient for the diagnosis of breast cancer progression, the finding of tumor cells in the CSF is pathognomonic for leptomeningeal disease.
In this study, we demonstrated the feasibility of isolating CSFTCs using IE/FACS. Isolated CSFTCs were subjected to extensive molecular analyses, which confirmed their malignant origin. Copy number analysis of CSFTCs demonstrated a wide range of genomic aberrations frequently found in primary breast tumors. Furthermore, gene expression profiling confirmed the epithelial nature of the CSFTCs and demonstrated that they were readily distinguishable from the leukocyte population present in the CSF.
It is possible that our anti-EPCAM-based IE strategy may have missed tumor cells in the CSF with low EPCAM expression, which has been proposed in the case of CTC detection (26, 27) . However, in this study of 15 patients with leptomeningeal disease, all were positive for CSFTCs using anti-EPCAM-based enrichment.
The evolutionary relationship between these metastatic cells in the CSF and the originating primary tumor is unknown. A recent study focused on HER2 FISH on CSFTCs, and suggested high concordance (14 out of 16) of HER2 copy status between CSFTCs and the primary tumor (28) . We also observed high concordance between HER2 status of the CSFTCs and clinical HER2 of the corresponding primary tumor.
Our approach has yielded new insights into CSFTCs and their relationship with primary tumor tissue at the genome-wide level. Direct comparative analysis of CSFTCs and matched tumor samples, including primary tumors from the same patient, revealed conserved copy number alterations and clear evidence of clonality. We also observed divergence, including significantly more overall genomic aberrancy in CSFTCs than in the corresponding primary tumor, as well as specific genomic regions frequently altered in CSFTCs but not primary tumors.
Research. CAN-13-2051 Given the limited sample size of this pilot study, testing in a larger cohort is warranted, especially in patients with HER2 positive disease where the incidence of CNS metastasis and leptomeningeal spread is more common (29) .
Molecular profiling of CSFTCs may lead to the discovery of candidate biomarkers and therapeutic targets relevant to CNS metastasis. For example, alterations including 8q24 (MYC) gain was observed in our cohort, suggesting opportunities for new targeted therapeutic strategies.
We also demonstrated the feasibility and reproducibility of profiling CSFTCs from serial samples. Given the potential for serial analysis, further applications in real-time assessments of tumor evolution, monitoring of therapeutic effects, and personalization of therapy can be envisioned.
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